|
|
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase I, Multi-Center, Open-Label, Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors Who Have Failed Standard Therapy or for Whom No Standard Therapy Exists
The purpose of the study is to investigate the safety, biodistribution, radiation dosimetry and pharmacokinetics of I-131-CLR1404.
100 Clinical Results associated with Cellectar, Inc.
0 Patents (Medical) associated with Cellectar, Inc.
100 Deals associated with Cellectar, Inc.
100 Translational Medicine associated with Cellectar, Inc.